)
Visual21 Oct 2025
Hermès' growth by geographical region visualized
Faron Pharmaceuticals (FARON) investor relations material
Faron Pharmaceuticals H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary27 Aug, 2025
Executive summary
Achieved significant clinical and financial milestones in H1 2025, including positive Phase II results and full enrollment for bexmarilimab in high-risk myelodysplastic syndrome (HR MDS), and regulatory progress.
Advanced lead asset BEX (bexmarilimab) for HR MDS, with promising efficacy and safety data, and secured orphan drug designations from FDA and EMA.
Strengthened management and board with experienced pharma professionals to support business development and commercial strategy.
Presented data at major scientific congresses and published in top-tier journals, highlighting strong clinical progress.
Financial highlights
Ended H1 2025 with a cash balance of EUR 13.5 million, down from EUR 30.0 million in 2024, maintaining a strong financial position.
Operating loss for H1 2025 was EUR -11.9 million, compared to EUR -11.3 million in H1 2024.
Loss per share improved to EUR 0.18 from EUR 0.20 year-over-year.
R&D expenses increased to EUR 7.1 million from EUR 6.7 million year-over-year, mainly due to clinical program advancement.
Net assets were EUR -16.7 million at period end, compared to EUR 1.4 million in 2024.
Outlook and guidance
Preparations underway for a large, multicenter, multinational Phase II/III trial in frontline HR MDS, targeting 80–90 sites across the US, Europe, and Japan, with first patient-in expected in H2 2025.
Cash runway extends into Q1 2026, with flexibility to draw additional tranches from the convertible bond arrangement.
Accelerated approval for BEX in frontline HR MDS possible as early as 2028.
Ongoing partnering discussions, supported by a top-tier investment bank, to maximize shareholder value and support further development.
Partnering strategy: regional vs. global deal balance?
FINPROVE: Why CLEVER-1 as inclusion criteria?
When will the discretionary EUR 10M tranche be drawn?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Faron Pharmaceuticals earnings date
ESMO Congress 202523 Oct, 2025
Next Faron Pharmaceuticals earnings date
ESMO Congress 202523 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Faron Pharmaceuticals is a Finland-based clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and other serious conditions. The company’s research targets immune system modulation to treat aggressive diseases with unmet medical needs. Faron Pharmaceuticals is headquartered in Turku, Finland, and its shares are listed on the AIM.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage